3005889-81-3

Product Details:

CasNo： 3005889-81-3

Molecular Formula： C343H550N94O116

Appearance： White to off-white Powder

Packing： Bottle

Throughput： 1KG/Month

Purity： 99%

Synonyms: Amycretin, NN‑9487, NNC0487‑011

CAS Number: 3005889‑81‑3

Molecular Formula: C₃₄₃H₅₅₀N₉₄O₁₁₆

Molecular Weight: 7846.6 Da

Description: White to off‑white lyophilized powder, commonly supplied as trifluoroacetate (TFA) salt.

Solubility: Soluble in dilute acetic acid; moderate solubility in pure water.

Modification: C18 di‑acid fatty‑acid acylation via linker for albumin‑binding to extend in‑vivo half‑life.

Mechanism of Action Zenagamtide is a unimolecular peptide co‑agonist for GLP‑1 receptor and amylin (AMYR / calcitonin) receptor. One single peptide molecule triggers two complementary satiety‑regulating pathways:

1. GLP‑1 pathway: glucose‑dependent insulin secretion, glucagon suppression, appetite reduction.
2. Amylin pathway: additional satiety signaling, suppress post‑prandial glucagon, further reduce food intake. Different from CagriSema (combination of two separate peptides), Zenagamtide delivers fixed‑ratio dual‑receptor activation by one single molecule.

Main Applications For research laboratory use only, NOT for clinical treatment or cosmetic formulation. ‑ Pharmacology research for type‑2 diabetes and obesity / weight‑management. ‑ Pre‑clinical and clinical trial material; subcutaneous once‑weekly and oral once‑daily dosage forms are under Phase 2 / Phase 3 clinical development by Novo Nordisk. Clinical data demonstrated significant HbA1c reduction and up to 14.6% body‑weight loss in T2D subjects.

Typical Specifications ‑ HPLC Purity: ≥95% / ≥98% ‑ Single maximum impurity: ≤2.0 %

Storage Condition Keep tightly sealed at ‑20℃ under dark condition. Avoid repeated freeze‑thaw cycles.

Important Note: This investigational peptide has NOT obtained marketing authorization anywhere in the world. It shall be used solely for scientific‑research purposes.